Singla Abhinav, Iking-Konert Christof, Kellersmann Carolin, Mougiakakos Dimitrios, Feist Eugen
Helios Fachklinik Vogelsang-Gommern, Sophie-von-Boetticher-Str. 1, 39245, Vogelsang-Gommern, Deutschland.
Stadtspital Zürich, Zürich, Schweiz.
Z Rheumatol. 2025 Jun;84(5):387-397. doi: 10.1007/s00393-025-01658-4. Epub 2025 May 26.
Systemic rheumatic diseases represent a heterogeneous group of conditions associated with significant morbidity and substantial healthcare burden. Their clinical course varies widely and is influenced by genetic, immunologic, and environmental factors. Despite advances in pharmacotherapy, conventional immunomodulatory and immunosuppressive treatments often remain insufficiently effective or lose efficacy over time. The identification of novel molecular targets is crucial to enable more precise and effective therapies. Advances in understanding pathogenic signaling pathways have led to the development of innovative therapeutic agents. This review highlights current and emerging molecular and cell-based therapies that are either recently approved or in clinical development, with a special focus on their mechanisms of action and potential to support personalized treatment approaches in rheumatic diseases.
系统性风湿性疾病是一组异质性疾病，与显著的发病率和巨大的医疗负担相关。它们的临床病程差异很大，并受到遗传、免疫和环境因素的影响。尽管药物治疗取得了进展，但传统的免疫调节和免疫抑制治疗往往效果欠佳或随着时间推移失去疗效。识别新的分子靶点对于实现更精确有效的治疗至关重要。对致病信号通路认识的进展已促成了创新治疗药物的开发。本综述重点介绍了最近获批或正在临床开发的基于分子和细胞的现有及新兴疗法，特别关注其作用机制以及支持风湿性疾病个性化治疗方法的潜力。
